TAG:
pathology associates
Seattle Hospital Lab JVs Involve Quest & LabCorp
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: Joint ventures and collaborative business relationships between hospital laboratories and commercial laboratories continue to be a difficult business model. Recent events in Seattle demonstrate the challenges and frustrations of establishing such ventures, then making them su…
“September 29, 2003 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
There was cautious optimism among lab industry leaders lobbying Congress to stop the proposed 20% co- payment for Part B laboratory testing services. It seems that, over the summer break, Iowa Senator Charles Grassley got a lesson in grass roots lobbying. At a number of town meetings, irate seniors s…
Needless Mastectomy Draws National Attention
By Robert Michel | From the Volume X No. 2 – February 10, 2003 Issue
CEO SUMMARY: This widely-reported case of misdiagnosis at an Allina hospital in St. Paul, Minnesota is a powerful reminder to pathology practices and clinical laboratories that breakdowns in medical quality will draw increasing attention and scrutiny. Both the patient and the community ar…
Unilab Files Registration For IPO of $115 Million
By Robert Michel | From the Volume VIII No. 7 – May 21, 2001 Issue
CEO SUMMARY: During the 1990s, Unilab used the twin strategies of lab acquisitions and aggressive sales and marketing to fuel rapid growth in specimen volumes and net revenues. However, California’s ultra-competitive managed care market and severe financial problems during the latter ha…
New CEO Takes Charge At Pathology Partners
By Robert Michel | From the Volume VII No. 8 – May 30, 2000 Issue
CEO SUMMARY: Pathology Partners, Inc. got a new President and CEO this month. The company is organized to build and operate independent regional histology and cytology laboratories in support of anatomic pathologists. Its business model is different than competing pathology companies and …
2000’s Movers & Shakers Represent Strong Leaders
By Robert Michel | From the Volume VII No. 5 – March 27, 2000 Issue
CEO SUMMARY: Its time again for THE DARK REPORT to make its yearly selection of the lab industry’s Movers & Shakers. Individuals chosen for 2000 represent a cross section of laboratory companies. Their successes demonstrate that leadership and vision continue to make a difference, d…
AmeriPath Pursues Ambitious Strategy Of Rapid Expansion
By Robert Michel | From the Volume VII No. 4 – March 6, 2000 Issue
CEO SUMMARY: As the pathology profession’s only publicly-traded physician practice management company, AmeriPath is the spear point of far-reaching changes now transforming pathology. With an annual revenue run rate of $270 million and an ample war chest of growth capital, AmeriPath int…
Winners and Losers in the Lab Industry
By R. Lewis Dark | From the Volume VII No. 1 – January 3, 2000 Issue
NOTHING WAS EASY FOR COMMERCIAL AND HOSPITAL LABS during the past decade. Reimbursement for lab tests was slashed. Onerous compliance requirements for Medicare increased costs and added to the legal risk of operating a laboratory. Patient access was restricted through exclusive HMO and managed care c…
“November 22, 1999 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VI No. 16 – November 22, 1999 Issue
UroCor, Inc. of Oklahoma City, Oklahoma is losing its long-time Chairman and CEO. Effective December 31, 1999, William A. Hagstrom will leave the company to pursue “new business start-up activities.” Hagstrom joined UroCor back in 1989, and helped it emerge from a Chapter 11 bank…
UroCor, Unilab, AmeriPath, MedPartners, Epitope
By Robert Michel | From the Volume VI No. 14 – October 11, 1999 Issue
UROCOR INKS PACT TO MATCH DIAGNOSTICS WITH THERAPEUTICS HERE’S A PIONEERING EFFORT to more closely link diagnostics and therapeutics into a single product package. UroCor, Inc. and Mallinckrodt, Inc. signed an agreement that allows Mallinckrodt to sell an…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized